Xuyong Wei
Overview
Explore the profile of Xuyong Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Xiang Z, Song Y, Liu J, Xu C, Zhou Z, Li J, et al.
Int J Surg
. 2024 Jan;
110(4):2196-2206.
PMID: 38285095
Background: Impact of preoperative infection on liver transplantation (LT) needs further investigation. Materials And Methods: From 1 January 2015 to 31 December 2022, 24 122 eligible patients receiving LT were...
32.
Wang K, Gao F, Dong S, Ding J, Dong L, Shao C, et al.
Hepatobiliary Surg Nutr
. 2023 Dec;
12(6):854-867.
PMID: 38115922
Background: Salvage liver transplantation (SLT) has been reported to be an efficient treatment option for patients with recurrent hepatocellular carcinoma (HCC) after liver resection (LR). However, for recipients who underwent...
33.
Xu N, Zhuo J, Chen Y, Su R, Chen H, Zhang Z, et al.
Br J Cancer
. 2023 Dec;
130(2):201-212.
PMID: 38040817
Background: N4-acetylcytidine (ac4C) is a conserved and abundant mRNA modification that controls protein expression by affecting translation efficiency and mRNA stability. Whether the ac4C modification of mRNA regulates hepatocellular carcinoma...
34.
Yu J, Ling S, Hong J, Zhang L, Zhou W, Yin L, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 38030304
Background: Immunotherapy has facilitated great breakthroughs in the treatment of hepatocellular carcinoma (HCC). However, the efficacy and response rate of immunotherapy are limited and vary among different patients with HCC....
35.
Wang K, Dong L, Lu Q, Yang Z, Fan X, Gao F, et al.
Int J Surg
. 2023 Nov;
109(12):4135-4144.
PMID: 37988413
Introduction: In order to maximize the utilization of precious donor liver, precisely determining potential hepatocellular carcinoma (HCC) candidates who will benefit from liver transplantation (LT) is essential. As a crucial...
36.
Tang L, Pan S, Wei X, Xu X, Wei Q
Mol Ther
. 2023 Oct;
31(11):3146-3162.
PMID: 37803832
Chimeric antigen receptor T cells (CAR-T) therapy has shown great potential in tumor treatment. However, many factors impair the efficacy of CAR-T therapy, such as antigenic heterogeneity and loss, limited...
37.
He X, Xu S, Tang L, Ling S, Wei X, Xu X
Int J Surg
. 2023 Oct;
110(1):406-418.
PMID: 37800536
Research on liver transplantation (LT) for liver cancer has gained increasing attention. This paper has comprehensively described the current status, hotspots and trends in this field. A total of 2991...
38.
Song Y, Lu Z, Shu W, Xiang Z, Wang Z, Wei X, et al.
Cell Insight
. 2023 Sep;
2(5):100115.
PMID: 37719773
Liver diseases are a major health issue, and prolonged liver injury always progresses. Advanced liver disorders impair liver regeneration. Millions of patients die yearly worldwide, even with the available treatments...
39.
Wang S, Xu N, Wang J, Chen Y, Li W, Chen H, et al.
Cancer Lett
. 2023 Aug;
571:216336.
PMID: 37562671
The efficacy of HCC (hepatocellular carcinoma) immunotherapy is hindered by the limited reactivity and short duration of tumor-infiltrating T cells. These deficiencies may be ascribed to the proliferative ability of...
40.
Zhang R, Shao S, Piao Y, Xiang J, Wei X, Zhang Z, et al.
Adv Mater
. 2023 Jul;
35(46):e2303614.
PMID: 37490011
Ionizable cationic lipids are recognized as an essential component of lipid nanoparticles (LNPs) for messenger RNA (mRNA) delivery but can be confounded by low lipoplex stability with mRNA during storage...